Literature DB >> 26556961

A joint model of persistent human papillomavirus infection and cervical cancer risk: Implications for cervical cancer screening.

Hormuzd A Katki1, Li C Cheung2, Barbara Fetterman3, Philip E Castle4, Rajeshwari Sundaram5.   

Abstract

New cervical cancer screening guidelines in the US and many European countries recommend that women get tested for human papillomavirus (HPV). To inform decisions about screening intervals, we calculate the increase in precancer/cancer risk per year of continued HPV infection. However, both time to onset of precancer/cancer and time to HPV clearance are interval-censored, and onset of precancer/cancer strongly informatively censors HPV clearance. We analyze this bivariate informatively interval-censored data by developing a novel joint model for time to clearance of HPV and time to precancer/cancer using shared random-effects, where the estimated mean duration of each woman's HPV infection is a covariate in the submodel for time to precancer/cancer. The model was fit to data on 9,553 HPV-positive/Pap-negative women undergoing cervical cancer screening at Kaiser Permanente Northern California, data that were pivotal to the development of US screening guidelines. We compare the implications for screening intervals of this joint model to those from population-average marginal models of precancer/cancer risk. In particular, after 2 years the marginal population-average precancer/cancer risk was 5%, suggesting a 2-year interval to control population-average risk at 5%. In contrast, the joint model reveals that almost all women exceeding 5% individual risk in 2 years also exceeded 5% in 1 year, suggesting that a 1-year interval is better to control individual risk at 5%. The example suggests that sophisticated risk models capable of predicting individual risk may have different implications than population-average risk models that are currently used for informing medical guideline development.

Entities:  

Keywords:  HPV; cancer screening; joint modeling of longitudinal; medical guidelines; risk modeling; survival data

Year:  2015        PMID: 26556961      PMCID: PMC4635446          DOI: 10.1111/rssa.12101

Source DB:  PubMed          Journal:  J R Stat Soc Ser A Stat Soc        ISSN: 0964-1998            Impact factor:   2.483


  29 in total

1.  Analysis of clustered and interval censored data from a community-based study in asthma.

Authors:  Scarlett L Bellamy; Yi Li; Louise M Ryan; Stuart Lipsitz; Marina J Canner; Rosalind Wright
Journal:  Stat Med       Date:  2004-12-15       Impact factor: 2.373

2.  Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.

Authors:  Hormuzd A Katki; Mark Schiffman; Philip E Castle; Barbara Fetterman; Nancy E Poitras; Thomas Lorey; Li C Cheung; Tina Raine-Bennett; Julia C Gage; Walter K Kinney
Journal:  J Low Genit Tract Dis       Date:  2013-04       Impact factor: 1.925

3.  A modeling framework for the analysis of HPV incidence and persistence: a semi-parametric approach for clustered binary longitudinal data analysis.

Authors:  Xiangrong Kong; Ronald H Gray; Lawrence H Moulton; Maria Wawer; Mei-Cheng Wang
Journal:  Stat Med       Date:  2010-12-10       Impact factor: 2.373

4.  Latent-model robustness in joint models for a primary endpoint and a longitudinal process.

Authors:  Xianzheng Huang; Leonard A Stefanski; Marie Davidian
Journal:  Biometrics       Date:  2009-01-23       Impact factor: 2.571

5.  A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion.

Authors:  Martyn Plummer; Mark Schiffman; Philip E Castle; Delphine Maucort-Boulch; Cosette M Wheeler
Journal:  J Infect Dis       Date:  2007-04-16       Impact factor: 5.226

Review 6.  HPV testing and vaccination in Europe.

Authors:  Simon C Leeson; Tamar Alibegashvili; Marc Arbyn; Christine Bergeron; Carmine Carriero; Jean-Luc Mergui; Pekka Nieminen; Walter Prendiville; Charles W E Redman; Gudrun C Rieck; Jens Quaas; K Ulrich Petry
Journal:  J Low Genit Tract Dis       Date:  2014-01       Impact factor: 1.925

7.  Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections.

Authors:  Ana Cecilia Rodríguez; Mark Schiffman; Rolando Herrero; Sholom Wacholder; Allan Hildesheim; Philip E Castle; Diane Solomon; Robert Burk
Journal:  J Natl Cancer Inst       Date:  2008-03-25       Impact factor: 13.506

8.  Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach.

Authors:  Cécile Proust-Lima; Jeremy M G Taylor
Journal:  Biostatistics       Date:  2009-04-15       Impact factor: 5.899

9.  Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.

Authors:  Francesca Carozzi; Anna Gillio-Tos; Massimo Confortini; Annarosa Del Mistro; Cristina Sani; Laura De Marco; Salvatore Girlando; Stefano Rosso; Carlo Naldoni; Paolo Dalla Palma; Manuel Zorzi; Paolo Giorgi-Rossi; Nereo Segnan; Jack Cuzick; Guglielmo Ronco
Journal:  Lancet Oncol       Date:  2012-12-21       Impact factor: 41.316

10.  Making predictions from complex longitudinal data, with application to planning monitoring intervals in a national screening programme.

Authors:  M J Sweeting; S G Thompson
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2012-04       Impact factor: 2.483

View more
  5 in total

1.  Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records.

Authors:  Li C Cheung; Qing Pan; Noorie Hyun; Mark Schiffman; Barbara Fetterman; Philip E Castle; Thomas Lorey; Hormuzd A Katki
Journal:  Stat Med       Date:  2017-06-28       Impact factor: 2.373

2.  A progressive three-state model to estimate time to cancer: a likelihood-based approach.

Authors:  Eddymurphy U Akwiwu; Thomas Klausch; Henriette C Jodal; Beatriz Carvalho; Magnus Løberg; Mette Kalager; Johannes Berkhof; Veerle M H Coupé
Journal:  BMC Med Res Methodol       Date:  2022-06-27       Impact factor: 4.612

Review 3.  Targeting Persistent Human Papillomavirus Infection.

Authors:  Srinidhi Shanmugasundaram; Jianxin You
Journal:  Viruses       Date:  2017-08-18       Impact factor: 5.048

4.  A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs.

Authors:  Maria Demarco; Noorie Hyun; Olivia Carter-Pokras; Tina R Raine-Bennett; Li Cheung; Xiaojian Chen; Anne Hammer; Nicole Campos; Walter Kinney; Julia C Gage; Brian Befano; Rebecca B Perkins; Xin He; Cher Dallal; Jie Chen; Nancy Poitras; Marie-Helene Mayrand; Francois Coutlee; Robert D Burk; Thomas Lorey; Philip E Castle; Nicolas Wentzensen; Mark Schiffman
Journal:  EClinicalMedicine       Date:  2020-04-25

5.  Reconstructing contact network structure and cross-immunity patterns from multiple infection histories.

Authors:  Christian Selinger; Samuel Alizon
Journal:  PLoS Comput Biol       Date:  2021-09-15       Impact factor: 4.475

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.